A Randomized, Double-blinded, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HS-10353 in Participants With Postpartum Depression
Latest Information Update: 12 Jul 2023
At a glance
- Drugs HS 10353 (Primary)
- Indications Postnatal depression
- Focus Therapeutic Use
- Sponsors Jiangsu Hansoh Pharmaceutical
Most Recent Events
- 12 Jul 2023 New trial record